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Clinical consequences of PKHD1 mutations in 164 patients with
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Background. ARPKD is associated with mutations in the
PKHD1 gene on chromosome 6p12. Most cases manifest peri-
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/neonatally with a high mortality rate in the first month of life
while the clinical spectrum of surviving patients is much more
variable than generally perceived.
Methods. We examined the clinical course of 164 neonatal
survivors (126 unrelated families) over a mean observation pe-
riod of 6 years (range 0 to 35 years). PKHD1 mutation screening
was done by denaturing high-performance liquid chromatogra-
phy (DHPLC) for the 66 exons encoding the 4074 aa fibro-
cystin/polyductin protein.
Results and Conclusion. This is the first study that reports the
long-term outcome of ARPKD patients with defined PKHD1
mutations. The 1- and 10-year survival rates were 85% and 82%,
respectively. Chronic renal failure was first detected at a mean
age of 4 years. Actuarial renal survival rates [end point defined
as start of dialysis/renal transplantation (RTX) or by death due
to end-stage renal disease (ESRD)] were 86% at 5 years, 71%
at 10 years, and 42% at 20 years. All but six patients (92%) had
a kidney length above or on the 97th centile for age. About
75% of the study population developed systemic hypertension.
Sequelae of congenital hepatic fibrosis and portal hypertension
developed in 44% of patients and were related with age. Posi-
tive correlations could further be demonstrated between renal
and hepatobiliary-related morbidity suggesting uniform disease
progression rather than organ-specific patterns. PKHD1 mu-
tation analysis revealed 193 mutations (70 novel ones; 77%
nonconservative missense mutations). No patient carried two
truncating mutations corroborating that one missense muta-
tion is indispensable for survival of newborns. We attempted to
set up genotype-phenotype correlations and to categorize mis-
sense mutations. In 96% of families we identified at least one
mutated PKHD1 allele (overall detection rate 76.6%) indicat-
ing that PKHD1 mutation screening is a powerful diagnostic
tool in patients suspected with ARPKD.
Autosomal-recessive polycystic kidney disease
(ARPKD) (MIM 263200) occurs with a proposed
incidence of 1:20,000 to 1:40,000 [1–3]. Principal his-
tologic manifestations involve the fusiform dilation
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of renal collecting ducts and distal tubuli as well as
dysgenesis of the hepatic portal triad known as ductal
plate malformation (hyperplastic biliary ducts and
congenital hepatic fibrosis). The majority of cases are
identified late during pregnancy or in the neonatal
period. However, fetal sonography does not allow an
early and reliable prenatal diagnosis of ARPKD as
even late midtrimester sonography often fails to detect
enlargement and increased echogenicity of kidneys
or oligohydramnios [4–6]. Severely affected fetuses
display a “Potter” phenotype with massively enlarged
kidneys. According to present estimates, up to 30% to
50% of all patients die shortly after birth from respira-
tory insufficiency, while renal failure is rarely a cause
of neonatal demise. Advances in renal replacement
therapy have improved the survival rates of ARPKD
patients and some of them reach adulthood. However,
life expectancy is still significantly diminished. A wide
range of ARPKD-related morbidities frequently evolve,
including systemic hypertension, end-stage renal disease
(ESRD), and sequelae of congenital hepatic fibrosis
(CHF) [7, 8].
The recent characterization of the PKHD1 gene (MIM
606702) on chromosome 6p12 provided the basis for di-
rect genotyping in ARPKD [9, 10]. PKHD1 is an ex-
ceptionally large gene. The longest open reading frame
(ORF) transcript comprises 67 exons encoding a pro-
tein of 4074 amino acids. Expression analysis suggests
that PKHD1 and its murine ortholog undergo a com-
plex pattern of alternative splicing [10, 11]. The predicted
full-length protein (fibrocystin/polyductin) represents a
novel putative integral membrane protein with so far un-
known function. Protein expression in kidney and liver
has been shown to be consistent with the sites affected
by the disorder. Recent studies have demonstrated fibro-
cystin/polyductin, in common with many other cystopro-
teins, to be localized to primary cilia and the basal body
[12–15]. This adds to the growing body of data suggesting
a causative role for this organelle in cystic renal diseases
[16–20].
The large size of PKHD1, its supposed complicated
pattern of splicing and lack of knowledge of the encoded
protein’s function(s) pose significant challenges to DNA-
based diagnostic testing. Moreover, the wide variety of
different PKHD1 mutations with most changes unique to
single families sets further requirements for investigation.
In a previous study, preliminary genotype-phenotype cor-
relations could be drawn for the type of mutation rather
than for the site of the individual mutation [21]. All pa-
tients carrying two truncating mutations displayed a se-
vere phenotype with peri- or neonatal demise. In other
terms, survival of the first month of life obviously requires
the presence of at least one parental PKHD1 missense
allele.
The present study aimed to (1) define the mutational
spectrum and mutation detection rate in ARPKD fami-
lies with at least one neonatal survivor, (2) evaluate the
long-term clinical course in ARPKD patients with de-
fined PKHD1 mutations, and (3) extend our knowledge
on clinical consequences of PKHD1 mutations.
METHODS
Selection of the study population
Fourty-two centers provided clinical information for
227 patients. Of these, 186 (97 males and 89 females) met
our inclusion criteria and had sufficiently documented
data for analysis. In all but four cases, inclusion of pa-
tients was based on the demonstration of typical clinical
features with characteristic ultrasonographic findings [22,
23] and absence of renal cysts in parental ultrasounds. In
two cases, no parental ultrasound data were available,
whereas the mother of two affected children exhibited
two renal cysts in her left kidney. In those patients fur-
ther proof of ARPKD was requested. In one patient this
was done by parental consanguinity with homozygous
haplotypes for chromosome 6p12 markers in the index
patient, in the other cases by demonstration of CHF by
liver biopsy. Patients were excluded if they had an af-
fected parent suggesting autosomal-dominant polycystic
kidney disease (ADPKD) or additional malformations.
In a total of 26 families, the diagnosis of ARPKD was
substantiated by kidney (N = 7) or liver biopsy (N = 24)
(in five cases combined kidney-liver biopsy). In 14 pedi-
grees, necropsy was performed in an affected individual.
Clinical data (up to 1995) of 29 families (46 patients) in
this series and mutations of 21 pedigrees were published
previously [21, 24] (Table 1). DNA or blood samples were
obtained on the basis of informed consent from these
ARPKD patients representing 126 apparently unrelated
nuclear families with at least one affected child who sur-
vived the neonatal period. The study population repre-
sented diverse nationalities from 24, mainly European,
countries. Most families have been attended by mem-
bers of the German Study Group of Pediatric Nephrol-
ogy [Arbeitsgemeinschaft fu¨r Pa¨diatrische Nephrologie,
(APN)]. The mean observation period was 6.0 years (0 to
35 years). Phenotypes were categorized as severe (peri-
natal or neonatal demise) (N = 22) or moderate (either
survived complications during the first month of life or
became first symptomatic beyond the neonatal period)
(N = 164).
Elevated serum creatinine levels were defined accord-
ing to Wassner [25] as mean values for age and height
greater than the 97th centile [>2 standard deviations
(SD)]. The glomerular filtration rate (GFR) was calcu-
lated from serum creatinine levels and height measure-
ments based on the estimated method of Schwartz et al
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Table 1.
Age at last
Patient Gender Origin examination/death Genotype
F2a,b F Finland Death (perinatal) Ex3: T36M (P)
F 20 years Ex3: T36M (M)
225 (C) F Turkey 1 year Ex14: F372L (P)
Ex14: F372L (M)
165 (C) M Turkey 7 years Ex16: I473S (P)
Ex16: I473S (M)
280 (C)b F Turkey 1 year Ex16: I473S (P)
F475 (C) F Lebanon Death (perinatal) Ex16: I473S (M)
M Death (perinatal) Ex32: N1744H (P)
M 2 years Ex32: N1744H (M)
153 (C) M Turkey 4 years Ex34: Y1838C (P)
Ex34: Y1838C (M)
244 (C) M Turkey 5 years Ex34: Y1838C (P)
Ex: Y1838C (M)
162 (C) F Turkey Death (23 years) Ex34: Y1838C (P)
Ex34: Y1838C (M)
160 (C)b M Turkey 2 years Ex37: I1998T (P)
Ex37: I1998T (M)
F495 M Morocco 1 year Ex53: V2771A (M)
Ex53: V2771A (P)
119 (C) M Turkey 11 years Ex54: I2851T (P)
Ex54: I2851T (M)
242 (C) F Turkey 6 months Ex58: H3124Y (P)
Ex58: H3124Y (M)
F267 (C) M India Death (perinatal) Ex58: G3178C (P)
M 4 years Ex58: G3178C (M)
297 F Finland 13 years Ex16: R496X (P)
Ex32: C1402F (M)
181 M Finland 5 years Ex16: R496X (M)
Ex34: S1862L (P)
F113a,b F Finland 5 years Ex16: R496X (P)
F 4 years Ex43: I2331K (M)
284b F Finland 17 years Ex16: R496X (P)
Ex61: V3471G (M)
F512 F Finland 2 years Ex16: R496X (P)
Ex61: V3471G (M)
223 F Germany 4 months Ex3: T36M (M)
Ex36: L1966fs (P)
123 M Germany Death (6 years) Ex3: T36M (M)
Ex61: Q3407X (P)
94 F Germany Death (5 months) Ex32: I1687T
M 17 years Ex61: Q3407X
F599 M Germany 6 years Ex37: I1998T (M)
F Death (3 weeks) Ex61: Q3407X (P)
198 M Germany 3 years Ex43: I2331K (P)
Ex61: Q3407X (M)
F3a,b F Finland 22 years IVS13: c.977-1G>A (P)
M Death (1 month) Ex43: 12331K (M)
230a M Israel Jew 11 years Ex9: I222V (P)
Ex32: A1254fs (M)
255 F The Netherlands 12 years Ex22: P755L (M)
Ex32: A1254fs (P)
172 M Israel Jew 12 years Ex32: A1254fs
F105b F Italy Death (perinatal) Ex54: R2840C
M Death (perinatal) Ex9: I222V (M)
F 8 years Ex58: R3240X (P)
F104 M Italy Death (perinatal) Ex32: C1472Y (M)
M 9 years Ex58: R3240X (P)
57a M Germany 19 years Ex5: R124X (P)
Ex16: G448R (M)
Ex18: L542S (M)
155a,b M Germany 8 years Ex27: A1030E (P)
Ex58: L3116fs (M)
161 M Germany 6 years Ex30: G1123S (P)
Ex37: Q2010fs (M)
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Table 1. continued.
Age at last
Patient Gender Origin examination/death Genotype
F329 F Czech Republic 5 years Ex32: I1687T (P)
F Death (8 months) Ex33: R1775X (M)
149 F France 27 years Ex23: R781X
Ex34: W1834C
311 M Germany 6 months Ex36: T1960A (P)
IVS39: c.6333-2A>G (M)
251 F Italy 5 years Ex37: S2016C (P)
Ex61: S3570X (M)
F48a M Belgium 35 years Ex36: N1919fs (P)
F 27 years Ex46: I2427T (M)
F578 F Turkey 20 years Ex43: I2331fs
M 12 years Ex53: R2795S
240 M Belgium 1 year Ex23: R781X (M)
Ex57: 12957T (P)
212 M Germany 1 year Ex58: H3124P (P)
Ex59: C3287X (M)
F59a,b M Turkey Death (1 year) Ex58: R3107X (P)
M Death (perinatal) Ex59: D3293V (M)
M Death (2 years)
F12a F Germany 33 years Ex3: T36M (M)
F 31 years Ex9: I222V (P)
F328 F Lebanon/Germany 7 years Ex3: T36M (M)
F 5 years Ex21: P676R (P)
262 M Czech Republic 14 years Ex3: T36M (M)
Ex26: H916P (P)
254 F Germany 1 year Ex3: T36M (M)
Ex26: L926P (P)
F17a M Germany 13 years Ex3: T36M (M)
M 10 years Ex30: G1123S (P)
M 7 years
F Germany 4 years Ex3: T36M (P)
238 F 1 year Ex32: C1237Y (M)
222 F Germany 6 years Ex3: T36M (P)
F 24 years Ex33: F1785L (M)
F313 F Germany Death (perinatal) Ex3: T36M (M)
M 13 years Ex33: V1789L (P)
186a M Germany 15 years Ex3: T36M (M)
Ex38: S2080N (P)
259 F Denmark 1 year Ex3: T36M (M)
Ex43: I2331K (P)
F371 F Austria 10 years Ex3: T36M (M)
M 8 years Ex46: C2422G (P)
M 6 years
206a M Germany 15 years Ex3: T36M (M)
Ex46: C2422G (P)
218 F Germany 1 year Ex3: T36M (M)
Ex56: V2884del (P)
F127b F Australia 7 years Ex3: T36M (M)
F Death (perinatal) Ex57: I2957T (P)
F549 F Germany Death (perinatal) Ex3: T36M (M)
M 6 years Ex58: A3097T (P)
F242 F Death (12 years) Ex3: T36M (P)
M Czech Republic Death (8 years) Ex58: R3240Q (M)
F 10 years
M 8 years
F1a,b F Finland Death (1 month) Ex3: T36M (P)
M 15 years Ex61: V3471G (M)
231a F Germany 7 years Ex3:T36M (P)
Ex61: L3543S (M)
183 M Germany 8 years Ex5: G112R
Ex16: Q504H
Ex27: M997K
F507 F Germany 1 year Ex43: I2331K (P)
M 4 months Ex55: S2861G (M)
Ex62: P3740S (M)
F383 M Bulgaria Death (perinatal) Ex4: R92G (M)
M 6 years Ex39: T2140P (P)
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Table 1. continued.
Age at last
Patient Gender Origin examination/death Genotype
F151a,b M Germany 5 years Ex21: W656C (M)
M Death (perinatal) Ex30: G1123S (P)
F4a M Germany 23 years Ex24: P805L/Ex58: I3177T (P)
M 20 years Ex50: W2690R (M)
F538 F Australia 1 year Ex24: P805L/ Ex58: I3177T (M)
Ex32: C1431S (P)
196a M Germany 9 years Ex27: I948S (M)
M 8 years Ex32: l1687T (P)
F236 M Portugal 7 years Ex30: E1124K (M)
M 5 years Ex58: R3240Q (P)
234 M Slovenia 1 year Ex32: L1407R (P)
Ex58: S3209R (M)
93a M Germany 12 years Ex32: P1486L (M)
Ex58: Y3155C (P)
219 M Germany 4 months Ex32: G1746R (P)
Ex34: Y1838C (M)
252 F Czech Republic 9 years Ex36: Q1923L (P)
Ex61: I3553T (M)
F55a F Germany 15 years Ex43: I2331K (P)
M 12 years Ex57: I2957T (M)
45 F Switzerland 4 years Ex57: I2957T (M)
Ex61: M3642T (M)
285 F Finland Death (9 months) Ex16: R496X (P)
260 F Finland 18 years Ex16: R496X (M)
F58 M Israel-Arab 10 years Ex36: L1966fs
F Death (2 months)
175 M Germany 6 years Ex36: L1966fs
122 M Germany 13 years Ex5: T128fs
F262 (C) F Turkey 10 years Ex14: P356fs
F 6 years
F 1 year
150b M Portugal 12 years Ex14: G369fs (M)
258b M Israel-Arab 14 years IVS16: c.1512+1G>A
263 F Switzerland 25 years IVS28: c.3228+1G>T
F92 M Brasil Death (1 month) Ex58: D3230fs (P)
M 1 year
142 F Germany 8 years Ex58: D3230fs (M)
F306 F Turkey 12 years Ex60: G3359fs
F 2 years
247 F Germany 12 years Ex61: Q3392X
195 F Switzerland Death (1 year) Ex61: S3570X (M)
F346 M Switzerland Death (perinatal) Ex61: Q3589X
F 12 years
F375 M Czech Republic Death (perinatal) Ex3: T36M
M 6 years
F32a,b M Germany Death (22 years) Ex3: T36M
F 17 years
F27a,b F Germany 13 years Ex3: T36M
F Death (3 years)
F9a,b F Germany 18 years Ex3: T36M
M 8 years
F231a,b M Slovenia 21 years Ex3: T36M
F 4 years
224 F Hungary Death (9 years) Ex3: T36M
111a,b F Germany 13 years Ex3: T36M (P)
117 M Germany 14 years Ex3: T36M
30 F Germany 17 years Ex3: T36M
202b F Czech Republic 6 years Ex3: T36M (M)
286 M Germany 3 years Ex3: T36M
F460 M Portugal 2 years Ex3: T36M (M)
F19a F Germany 16 years Ex9: I222V
M 15 years
10a F Germany 13 years Ex9: I222V (M)
236 M Austria 12 years Ex9: I222V
164 M Turkey 4 years Ex30: S1156L (M)
179 M Germany 2 months Ex30: S1156L
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Table 1. continued.
Age at last
Patient Gender Origin examination/death Genotype
232 F Czech Republic 11 years Ex5: F129S
F154 M United Kingdom Death (perinatal) Ex16: G466A (P)
F 6 years
F559 F French-Canadian 2 years Ex16: G466A (M)
65 M Germany 12 years Ex22: P755L
M Death (perinatal)
F0a F Germany 16 years Ex25: V865F
M 13 years
176 M Switzerland 6 years Ex27: A1030V
F608 F Bulgaria 24 years Ex32: S15841
F102a F Germany 11 years Ex33: C1787F
M 8 years
257 M Germany 6 years Ex43: I2331K (M)
5 F Germany 14 years Ex54: R2831K
F573 M Czech Republic 6 months Ex57: I2957T
F539 F Turkey 3 years Ex57: G2967W
M 1 year
81 M Germany 15 years Ex58: H3029P
8 F Germany 14 years Ex58: I3051T
M 25 years
F465 F Portugal 21 years Ex58: R3240Q
F 14 years
F316b F Germany 24 years Ex61: R3482C
M Death (perinatal)
96a F Germany 13 years Ex61: M3642T (M)
133 M Germany 8 years
F271 F Hungary 7 years
M 5 years
146 M Germany 3 years
249 M Czech Republic 6 years
158 M Germany 8 years
Abbreviations are: (C), parental consanguinity known; (P), paternally inherited allele; (M), maternally inherited allele; novel PKHD1 mutations are shown in bold   
characters.
aClinical data up to 1995 of this patient were included in Zerres et al (Acta Paediatr 85:437–445, 1996).
bMutation(s) of this family have been described in Bergmann et al (J Am Soc Nephrol 13:76–89, 2003).
Patients with a predominant liver phenotype (N = 15 defined as early esophageal variceal bleeding or ascites and (nearly) normal renal function) are shown on a
light gray background.
Patients requiring renal replacement therapy are shown on a gray background.
[26, 27]. In case data on height were missing in patients
with no documented growth retardation, these were ad-
justed by assuming an average height for age. Chronic
renal insufficiency (CRI) was defined as GFR <75% nor-
mal adjusted for age. Kidney length was measured by ul-
trasound in relation to height [28] and expressed as SD
scores. The date of diagnosis was requested for ARPKD-
related renal morbidities [e.g., systemic hypertension (de-
fined as the date antihypertensive therapy was initiated),
growth retardation (defined as height < 2 SD for age),
and occurrence of urinary tract infections (UTIs) (cys-
titis or pyelonephritis)]. The date of diagnosis was also
documented for ARPKD-related hepatobiliary morbidi-
ties [e.g., portal hypertension (defined by sonographic
evidence of hepatosplenomegaly and directional rever-
sal of portal vein flow), esophageal variceal bleeding,
splenomegaly, hypersplenism, and cholangitis]. When ap-
plicable, dates and results of kidney and liver biopsies as
well as transplantations were recorded. Patient data were
entered in a secure database and analyzed with Excel
(Microsoft). Comparisons between categorical variables
were analyzed with the v 2 test. Spearman’s rank order
correlation coefficient r was used to examine the rela-
tionship between age at onset of various comorbidities.
Kaplan-Meier curves were constructed for survival rates
and renal function. For all analyses, a P value of <0.05
was deemed statistically significant.
Haplotype analysis
At least two informative markers flanking PKHD1
were typed in each family with more than one child as
previously described [21, 29, 30]. All families were com-
patible with linkage to the PKHD1 locus on chromosome
6p12. In case of sporadic patients, a minimum of three in-
tragenic markers (D6S1344, D6S243, and D6S1714) were
tested to check for homozygous haplotypes in the index
patient. After identification of a recurrent PKHD1 mu-
tation, allele sharing analysis based on the mentioned
intragenic polymorphic sites was done in the respective
families to study a possible founder effect.
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Mutation analysis
Mutation screening was done for the 66 exons encoding
the 4074 aa polyductin protein (GenBank NM 138694)
by denaturing high-performance liquid chromatogra-
phy (DHPLC) on a Wave Fragment Analysis System
(Transgenomic, Crewe, UK), as recently described in de-
tail [31]. Samples exhibiting an aberrant elution profile
were subjected to direct sequence analysis. Once two mu-
tations had been identified in a patient, the altered alleles
were proven to reside on separate chromosomes by di-
rect sequencing of the parental DNA probes as far as
these were available (in any but four cases of the 72 pedi-
grees in whom both mutations were identified). DNA
samples from 200 apparently unrelated normal control
subjects were run under appropriate DHPLC conditions
to exclude a possible polymorphism or harmless sequence
variant in case of a missense mutation or subtle in-frame
change.
RESULTS
A total of 186 ARPKD patients (97 males and 89
females) representing 126 apparently unrelated nuclear
families were enrolled in the clinical and molecular di-
agnostic studies; 164 of these patients (83 males and 81
females) survived the neonatal period. In 48 pedigrees
more than one child was affected (multiplex families).
Twenty families were characterized by gross intrafamil-
ial phenotypic variability (peri-/neonatal demise in one
and survival into childhood in another affected sibling)
(Fig. 1). The mean observation period was 6 years (range
0 to 35 years). Of all patients, the mean age at last re-
ferral was 10.3 years. Ages at diagnosis of the study
cohort and initial clinical features of the 143 children di-
agnosed after birth are given in Table 2. Results for renal
function analysis, kidney lengths, and survival rates are
depicted in Figures 2 to 5 and did not reveal any statis-
tically significant gender difference. Correlations among
ARPKD comorbidities revealed a significant relationship
between the development of chronic renal failure (CRF)
and systemic hypertension (r = 0.99). Significant correla-
tions could be further demonstrated between renal and
hepatobiliary-related morbidity (between CRF and por-
tal hypertension, r = 0.84/between serum creatinine >200
lmol/L and portal hypertension, r = 0.70).
PKHD1 mutations
We performed a systematic mutation screen by
DHPLC of the 66 PKHD1 exons encoding the longest
continuous ORF. A total of 193 out of expected 252 mu-
tations (126 families) was observed corresponding to a
detection rate of 76.6%. Seventy of the mutations de-
tected were novel ones not reported previously. We were
able to characterize two underlying mutations in 72 fam-
ilies (57%) and one mutation in 49 pedigrees (39%). No
mutation could be detected in five families (4%). Thus,
in 96% of families one or two mutations were identi-
fied. In all individuals with two mutations, the mutant
alleles were proven to reside on separate chromosomes.
PKHD1 changes were dispersed over the protein’s entire
length with most mutations being unique to single fam-
ilies (“private mutations”). All mutations and polymor-
phisms/sequence alterations described so far are listed
on the PKHD1 mutation database (URL: http://www.
humgen.rwth-aachen.de).
The observed changes fell into two major groups:
missense (N = 149) (77%) and truncating mutations
(N = 44) (23%). Truncating alterations (23 nonsense, 17
frameshifting small deletions/insertions/duplications, and
four splice-site mutations) are expected to produce null
alleles. Canonical splice-site changes c.977 − 1G > A and
c.3228 + 1G > T likely lead to skipping of the affected
exon [31] with subsequent out-of-frame fusion of exons,
whereas the corresponding transcripts of c.1512 + 1G >
A missing exon 16 and c.6333 − 2A > G missing exon
40 may restore the reading frame and actually may not
merit the designation truncating.
About three fourths of the mutations were nonconser-
vative missense substitutions that were neither found in
controls nor previously described as polymorphisms [9,
10, 21, 31, 33–35]. All but twelve missense changes were
found to replace residues conserved in the murine or-
tholog (NM 153179). Missense changes not found to re-
place residues conserved in mouse polyductin were still
considered pathogenic as further evidence supports their
pathogenicity. First, the nature of each residue in the
murine ortholog was different from the amino acid in-
corporated by the mutation. Moreover, the mutations
R92G, H916P, I2331K, and R2840C were either con-
served in polyductin-like proteins from rat (XM 236979
and XM 236984) or chicken. The mutations I2331K,
R2840C, and I3177T have been described many times in
previous mutational studies [9, 10, 21, 31, 33, 34]. Finally,
the remaining changes each represent nonconservative
amino acid substitutions that can be expected to cause
considerable changes on protein structure.
Probands carrying putative missense substitutions
were included in the screen of the rest of the gene. No
more than a maximum of two putative pathogenic muta-
tions were observed in all but three cases. In any of these
patients (57, 183, and F507), both missense changes resid-
ing on the same parental chromosome were shown to be
nonconservative and affected amino acids conserved in
the mouse ortholog. Functional studies will be required to
assess the relative pathogenic potential of these changes.
Moreover, screening further patients for PKHD1 muta-
tions will also contribute to resolve the matter. Enrich-
ment of an alteration in the ARPKD population might
be good evidence that it is disease associated. Notably,
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Fig. 1. Summary of the clinical outcome of affected siblings of 48 multiplex pedigrees. Genotypes of families are given in the second column.
Males: squares; females: circles. Diagonal lines denote deceased patients. Different fillings of symbols are explained below the figure. Abbreviations
are: SCr, serum creatinine; RTX, renal transplantation; CAPD, continuous ambulatory peritoneal dialysis; HD, hemodialysis; portal HTN, portal
hypertension; LTX, liver transplantation.
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Fig. 1. (continued.)
Table 2. Ages and clinical features at diagnosis
Ages at diagnosis of the study cohort (N = 186)
Prenatal 23%
1st month 31%
2nd to 12th month 16%
2nd to 5th year 19%
>5th year 11%
Initial clinical features in children
diagnosed after birth (N = 143)
(more than one category possible)
Palpable abdominal masses 68%
Systemic hypertension 43%
Hepatosplenomegaly 21%
Urinary tract infection 12%
Respiratory distress 9%
Esophageal varices 5%
the substitutions G448R, M997K, and S2861G have been
described in other ARPKD patients further strengthen-
ing their pathogenic potential. In two other families (F4
and F538) the missense changes P805L and I3177T were
tandemly inherited on one parental allele [35].
PKHD1 sequence variants/polymorphisms
In addition to the putative pathogenic changes de-
scribed, a vast number of probably harmless polymor-
phisms and sequence variants were encountered. Alter-
ations were considered as neutral in case they were (1)
intronic changes beyond the consensus splice sites, (2) lo-
cated in the 5′ or 3′ UTR, (3) silent exonic changes (not
altering an amino acid), (4) a substitution which did not
segregate with the disease or was found in a set of 200
normal controls, or (5) already been described in previ-
ous studies [9, 10, 21, 31, 33–35]. Overall, we detected 20
amino acid substitutions, several of them of nonconser-
vative nature that were also present in normal chromo-
somes (Table 3). Notably, nine of those missense polymor-
phisms (45%) affect residues not conserved in the mouse
protein. Furthermore, we observed 28 silent exonic nu-
cleotide changes not causing an amino acid substitution
(Table 4) and 30 adjacent intronic sequence variations
(Table 5).
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Fig. 2. Kaplan-Meier curves were constructed for renal function analysis of the 164 neonatal survivors included in the present study. The lower
curve depicts the proportion of patients with serum creatinine levels below 100 lmol/L, the middle curve those of individuals with serum creatinine
values below 200 lmol/L, and the upper one indicates the proportion of patients without end-stage renal disease (ESRD) at a given age. Accordingly,
our study cohort revealed an actuarial renal survival rate (end point defined as start of dialysis/RTX or by death due to ESRD) of 86% at 5 years,
71% at 10 years, 66% at 15 years, and 42% at 20 years. At the end of the study, 38 patients received dialysis treatment for ESRD, were transplanted,
or died due to ESRD. Mutation types identified in these 38 patients are shown above the ESRD curve indicating the age when the respective
individual first received renal replacement therapy (X is truncating mutation, M is missense mutation, and − is an unidentified allele). The mean
age ESRD occurred in patients with a truncating mutation on one parental allele was 7.2 years (N = 16), in patients carrying missense changes on
both alleles 10.1 years (N = 11).
To determine whether some of these changes could dis-
rupt predicted splice sites and may, thus, have a potential
pathogenic impact, we generated splice-site scores (pre-
dicting the theoretic impact upon donor and acceptor site
strength and the probability that sequence changes cre-
ated novel splice sites) for the wild-type and variant se-
quences of those changes that were not identified among
normal controls. For this purpose we used the splice-site
prediction algorithm at http://www.fruitfly.org/seq tools/
splice.html. In cases where this algorithm did not predict
an acceptor/donor splice site neither for the wild-type nor
for the variant sequence, a further splice site prediction al-
gorithm at http://www.cbs.dtu.dk/services/NetGene2/ was
used. However, all but four variants did not result in any
change of the predicted splice-site score (maximum al-
teration from 86% to 50% for donor site in case of c.51A
> G/A17A). In principle, a pathogenic potential will ul-
timately need to be assessed by functional studies.
As the PKHD1 gene is predicted to comprise a min-
imum of 86 exons [10], we screened by DHPLC all
patients of the current study with one or no PKHD1
mutation in the longest ORF for changes in the pre-
dicted alternatively spliced exons (AY129465). Single nu-
cleotide changes involving these exons were observed
in several patients. However, most of these alterations
were also found among normal controls with compara-
ble allele distributions among patients and controls. The
changes g.157552C > T, g.175388A > C, g.344048A > T,
g.406265C > T have been identified in one patient each,
however, were also detected in one out of 400 control
chromosomes. Principally, a potential pathogenic impact
of these sequence variations has to await the definition
of transcripts containing alternative exons and their pre-
dicted reading frames.
Genotype-phenotype correlations
As previously described [21], all patients carrying a
termination-type mutation on both parental alleles died
shortly after birth, regardless of the site of the prema-
ture stop of translation. This observation has been subse-
quently confirmed by other studies on PKHD1 mutations
[31, 33, 34] and could also be corroborated by the present
survey in which no family with two truncating mutations
has been identified.
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Fig. 3. The development of serum creatinine (SCr) values of 22 patients (13 males and 9 females) with at least one serum creatinine level above
200 lmol/L during the observation period is depicted. The color of the curves indicates the mutation status of patients (red is the compound
of truncating and missense mutation; green is the missense mutation on both alleles; blue is the single truncating or missense change, second
mutation not identified). Patients whose first available serum creatinine value was already above 200 lmol/L (N = 16) are not included in this figure.
Deterioration of renal function rapidly set in above a serum creatinine level of about 200 lmol/L. Almost every patient who reached that point
developed end-stage renal disease (ESRD) within a period of less than 5 years. The mean age patients with a truncating mutation on one allele
reached a serum creatinine value of about 200 lmol/L was 4.1 years (N = 7), patients carrying missense changes on both alleles had a mean age of
7.2 years (N = 10).
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Fig. 5. Kaplan-Meier survival curve for all 186 individuals of the current series (overall survival rate at 1 year of age of 85% (81% males and 89%
females) (NS) with most cases of death in the peri-/neonatal period related to respiratory insufficiency). Of those patients who survived the first
month of life, 95% were alive at 1 year, 94% at 5 years, and 92% at 10 years. In total, a number of 13 neonatal survivors (8%) (6 males and 7 females)
died during the observation period at a median age of 5.6 years. Mutation types identified in these 13 patients are shown below the curve when the
respective individual passed away (X is truncating mutation; M is missense mutation; − is unidentified allele). In six patients death occurred during
the first year of life with predominant extrarenal causes [cardiorespiratory insufficiency (N = 3), end-stage renal disease (ESRD) with sepsis (N =
2), pneumonia (N = 1)]. ESRD with sepsis was also causative for demise in six patients at later ages of life (1 to 23 12 years). One male died at the
age of 22 years due to ESRD complicated by pneumonia and esophageal variceal bleeding. Perpendicular bars indicate the age of surviving patients
at last examination (censored patients).
Except for genotype-phenotype correlations estab-
lished for the type of mutations, there have been made
no efforts so far to determine the genetic contributions of
single missense alterations to the phenotypes observed.
Missense mutations may range in their effects from hy-
pomorphic alleles that allow for a milder clinical course
to complete loss of function variants resembling trun-
cating alterations. However, such correlations are ham-
pered given the lack of mutational hotspots and marked
allelic heterogeneity at PKHD1 with the majority of mu-
tations unique to a single family. Nevertheless, the bulk
of mutational data that has been identified since cloning
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 4. Kidney lengths measured by ultrasound related to age of 78 patients (40 male and 38 females) of the present study. In most individuals
multiple values at different ages were encountered, however, for clarity only initial and final values are presented. All but six patients (92%) had
a kidney length above or on the 97th centile for age ( = normal kidney length for age +2 SD scores). In males (squares), kidney lengths ranged
between +1 and +17 SD, in females (circles) between 0 and +12 SD. The color indicates the mutation status of patients (red is the compound of
truncating and missense mutation; green is the missense mutation on both alleles; blue is the single truncating or missense change, second mutation
not identified). Correlations were neither observed between kidney length and serum creatinine levels, between kidney length and duration of the
disease nor between kidney length and mutation type.
of PKHD1 should allow the start of categorizing mis-
sense mutations. Due to multiple allelism and the high
rate of different compound heterozygotes, our approach
was based on the premise that termination-type muta-
tions likely all have a uniform and devastating effect with
loss of function. Thus, one would expect the type and
position of missense changes to determine the clinical
course in compound heterozygotes with one truncating
and one missense mutation. In line with this hypothesis,
all missense mutations encountered in the present series
that occur in compound with a chain-terminating muta-
tion may rather be associated with a moderate phenotype.
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Table 3. PKHD1 amino acid substitutions also found among normal controls
cDNA/nucleotide Allele frequency
Location change aa change Mouse aa among controls References
Ex16 c.1463G > C R488P L486 1/200 21, 35, Current study
Ex19 c.1736C > T T579M T577 2/200 21, 35, Current studya
Ex22 c.2170C > T P724S P722 1/200 21, 35, Current study
Ex22 c.2278C > T R760C C758 46/200 9, 10, 21, 33–35, Current studya
Ex24 c.2489A > G N830S N828 3/200 21, 33, Current studya
Ex30 c.3407A > G Y1136C Y1134 1/200 21, 35, Current study
Ex32 c.3785C > T A1262V V1260 9/200 9, 21, 33, 35, Current studya
Ex53 c.8345G > C G2782A C2774 2/200 Current studya
Ex55 c.8606C > A T2869K V2863 10/200 21, 34, 35, Current Studya
Ex58 c.9215C > T A3072V A3066 1/200 21, 35, Current study
Ex58 c.9262G > A D3088N D3082 1/200 21, 35, Current study
Ex58 c.9320G > C R3107P G3101 1/200 21, 35, Current study
Ex58 c.9415G > T D3139Y N3132 4/200 9, 10, 21, 33–55, Current studya
Ex59 c.9577G > A V3193I V3186 2/200 Current studya
Ex61 c.10515C > T S3505R S3498 6/200 9, 33, Current studya
Ex65 c.11525G > T R3842L R3835 8/200 21, 35, Current studya
Ex66 c.11696A > G Q3899R Q392 50/200 9, 10, 21, 33–35, Current studya
Ex66 c.11714T > A I3905N K3898 1/200 Current studya
Ex67 c.11878G > A V3960I V3954 4/200 9, 10, 21, 35–35, Current studya
Ex67 c.12143A > G Q4048R Q4037 60/200 9, 21, 33, 35, Current studya
9Ward et al, 2002; 10Onuchic et al, 2002; 21Bergmann et al, 2003; 33Rossetti et al, 2003; 34Furu et al, 2003; 35Bergmann et al, 2004.
aSharp et al, database submission.
GenBank NT 007592.13; NM 138694.2; nucleotide +1 is the A of the ATG-translation initiation codon.
Albeit the dataset is still limited and this concept repre-
sents a simplified view, it might constitute a reasonable
approach to start classifying missense mutations into se-
vere and moderate/mild changes (Table 6).
The assessment of the character of a single missense
change may in particular come from patients homozy-
gous for a given amino acid substitution. F372L, N1744H,
V2771A, I2851T, H3124Y, and G3178C were observed
homozygously within the current study. A common an-
cestral origin in the Turkish population seems most likely
for the missense changes I473S and Y1838C.
Renal phenotypes of neonatal survivors of the present
and previous studies [9, 21, 33] who carry the same
set of PKHD1 mutations are compared in Figure 6.
Y1838C/Y1838C, I1687T/X, and V3471G/R496X re-
sulted in early ESRD, whereas T36M/C2422G and
I2331K/X were associated with minor renal disease.
DISCUSSION
Since the PKHD1 gene was only recently character-
ized, previous studies reporting ARPKD-related mor-
bidities merely described the clinical course of patients
without providing mutational data. On the other hand,
the initial studies describing PKHD1 mutations clearly
focused on molecular genetic aspects. We performed
PKHD1 mutation analysis in a cohort of 186 ARPKD
patients and examined the clinical course over a mean
observation period of 6 years. This is the first study that
combines PKHD1 mutations with long-term follow-up
data considerably extending the knowledge on genetic
contributions to phenotypes observed in ARPKD. This
information should provide a rational starting point to
further investigate genotype-phenotype correlations.
Clinical studies on ARPKD differed widely by their se-
lection criteria of patients and their mode of analysis of
data (Table 7). Patients of this and our previous study [24]
as well as of the survey by Guay-Woodford and Desmond
[7] were mostly recruited from departments of pediatric
nephrology. As a consequence, individuals with an early
lethal form of ARPKD are underrepresented. Capisonda
et al [37] and Gagnadoux et al [38] reported clinical out-
comes of patients from specialized single centers. Most
of the individuals in the study by Roy et al [8] had previ-
ously been reported by Kaplan et al [39] who exclusively
included patients with pathoanatomically proven CHF.
Ka¨a¨ria¨inen, Koskimies, and Norio [40] analyzed mainly
data obtained from Finnish death registers. Inclusion cri-
teria of the study by Cole, Conley, and Stapleton [41] were
diagnosis within the first year of life and survival of the
neonatal period.
Overall, our data suggest renal morbidities to be posi-
tively related with hepatobiliary morbidities rather than
organ-specific progression of ARPKD [7]. Thus, single
ARPKD patients with an organ-specific phenotype may
be regarded as exceptions to the rule. It might be promis-
ing to explore genotype-phenotype correlations and
(genetic) modifiers in these patients.
Mutation data
Overall, the diagnosis was substantiated in 96% of
pedigrees by identifying one or two PKHD1 mutations.
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Table 4. PKHD1 silent changes
Allele
cDNA frequency
nucleotide among
Exon change aa change controls SS WT SS variant Comment Reference
Ex2 c.51 > G A17A 0/200 D: 0.86 D: 0.50 Decreased strength of Novel
donor site
Ex4 c.214C > T L72L 25/200 21, 33–35, Current studya
Ex4 c.234C > T D78D 15/200 9, 21, Current studya
Ex14 c.999A > G E333E 6/200 21, 35, Current study
Ex15 c.1122A > C A374A 0/200 A: 0.96 A: 0.97 Probably no effect Novel
Ex15 c.1185T > C D395D 4/200 33, Current studya
Ex17 c.1587T > C N529N 10/200 9, 10, 21, 33–35, Current studya
Ex20 c.1950G > A R650R 0/200 D: 0.67 D: 0.67 Probably no effect Novel
Ex21 c.2046A > C P682P 20/200 21, 33–35, Current studya
Ex27 c.2853C > T T951T 2/200 9, 35, Current study
Ex30 c.3393G > A A1131A 1/200 21, 34, 35, Current study
Ex30 c.3537T > C N1179N 2/200 21, 35, Current studya
Ex32 c.3756G > C L1252L 7/200 9, 21, 33, Current Pagea
Ex32 c.4035C > A G1345G 0/200 A: 0.77 A: 0.77 Probably no effect Current studya
Ex32 c.4920A > C V1640V 1/200 9, 10, 21, 33–35, Current studya
Ex36 c.5896C > T L1966L 5/200 21, 34, 35, Current studya
Ex39 c.6462T > C V2154V 0/200 D: 0.78 D: 0.78 Probably no effect 21, Current study
Ex40 c.6636C > T A2212A 0/200 D: 1.00 D: 1.00 Probably no effect 21, Current study
Ex41 c.6777C > T F2259F 1/200 Novel
Ex43 c.6900C > T N2300N 1/200 21, 35, Current studya
Ex48 c.7587A > G G2529G 65/200 9, 10, 21, 33–35, Current studya
Ex49 c.7764A > G L2588L 20/200 9, 10, 21, 33–35, Current studya
Ex56 c.8673C > G R2891R 2/200 Current studya
Ex58 c.9237G > A A3079A 20/200 9, 10, 21, 33–35, Current studya
Ex58 c.9492C > T S3164S 1/200 9, 10, Current study
Ex61 c.10434T > A P3478P 4/200 9, 35, Current study
Ex61 c.10521C > T H3507H 5/200 9, 10, 21, 33–35, Current studya
Ex63 c.11340T > C P3780P 10/200 9, 10, 21, 33–35,
Current studya
Abbreviations are: SS, Splice-site score using the splice-site prediction algorithm at http://www.fruitfly.org/seq tools/splice.html; A, splice acceptor site; D, donor splice
site; WT, wild-type.
9Ward et al, 2002; 10Onuchic et al, 2002; 21Bergmann et al, 2003; 33Rossetti et al, 2003; 34Furu et al, 2003; 35Bergmann et al, 2004.
aSharp et al, database submission. GenBank NT 007592.13; NM 138694.2; nucleotide + 1 is the A of the ATG-translation initiation codon.
In total, 193 of 252 expected mutations (76.6%) could
be identified. Thus, our data suggest that the previous
relatively low mutation detection rates obtained among
patients with a milder clinical course were most likely
due to methodologic issues. Although the current rate is
lower than the 85% obtained in a recent study of ARPKD
patients with peri-/neonatal demise [31], this detection
rate is acceptable and makes PKHD1 mutation screen-
ing both robust and efficient for clinical use to establish
the diagnosis of ARPKD.
As described, most PKHD1 mutations are private and
recurrence of changes is often based on a common ances-
tral origin [35]. The most common mutation, c.107C > T
(T36M), has been described in each PKHD1 mutation
study reported to date [9, 10, 21, 31, 33–35] and accounts
for approximately 15% to 20% of mutated alleles. There
is conflicting data on whether it is an ancestral change or
occurs due to a frequent mutational event. Ultimately, it
cannot be excluded that some of the mutated c.107C >
T alleles represent a founder effect in the Central Euro-
pean population where it is particularly frequent. How-
ever, there is compelling evidence that T36M constitutes
a mutational “hotspot,” most likely due to methylation-
induced deamination of the mutagenic CpG dinucleotide
[36]. Within the present study, T36M was identified in a
multitude of obviously unrelated families of different eth-
nic origins on various haplotypes. For instance, patients
of nonconsanguineous Finnish family F2 homozygous for
c.107C > T were shown to harbor differing haplotypes.
Further evidence of recurrence and against a common an-
cestral origin of mutated c.107C > T alleles were demon-
strated by diverse haplotypes among German-Austrian
pedigrees F371 and ID206 carrying the same set of mis-
sense mutations (c.107C > T + c.7264T > G).
Given multiple allelism and a proposed carrier fre-
quency of approximately 1:70 in nonisolated populations
[2], the prevalence of any individual PKHD1 mutation
is expected to be low. Therefore, despite screening of
a large number of normal chromosomes, evidence from
segregation analysis, lack of further changes in the rest of
the gene, and nonconservative nature of amino acid sub-
stitutions, it cannot be definitely ruled out that some of
the PKHD1 missense changes will finally be revealed as
non-pathogenic. Enrichment of a certain PKHD1 change
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Table 5. Intronic PKHD1 polymorphisms/sequence variants
Allele
frequency
among
IVS Location controls SS WT SS variant Comment Reference
IVS2 c.53 − 24A > G 0/200 A: 0.82 A: 0.82 Probably no effect Novel
IVS7 c.527 + 19T > C 52/200 21, 39, 35, Current studya
IVS9 c.667 + 18C > T 0/200 D: ND (ND) D: ND (ND) Probably no effect Novel
IVS9 c.668 − 30T > C 1/200 21, 35, Current study
IVS15 c.1234 − 10T > A 6/200 34, 35, Current studya
IVS15 c.1234 − 5C > T 1/200 Current studya
IVS18 c.1694 − 33C > G 4/200 34, 35, Current studya
IVS19 c.1837 − 23A > G 0/200 A: 0.63 A: 0.63 Probably no effect Novel
IVS22 c.2279 + 13T > G 23/200 21, 33, 35, Current studya
IVS22 c.2280 − 35C > A 0/200 A: 0.77 A: 0.77 Probably no effect Novel
IVS23 c.2407 + 50C > T 82/200 21, 33, 35
IVS29 c.3365 − 6A > G 0/200 A: ND (0.95) A: ND (0.95) Probably no effect Novel
IVS32 c.5236 + 14A > G 11/200 21, 34, 35, Current studya
IVS35 c.5752 − 18del C 0/200 A: 0.97 A: 0.97 Probably no effect Novel
IVS37 c.6122 − 9C > G 0/200 A: 0.90 A: 0.83 Decreased strength of Novel
acceptor site
IVS46 c.7351 − 8A > T 0/200 A: 0.88 A: 0.97 Increased strength of Novel
acceptor site
IVS48 c.7734 − 19ins TT 0/200 A: ND (ND) A: ND (ND) Extension of Novel
polypyrimidine stretch
IVS48 c.7734 − 4T > C 35/200 35, Current studya
IVS49 c.7912 − 5T > G 0/200 A: ND (ND) A: ND (ND) Possibly decreased Novel
strength of acc. site
IVS52 c.8302 + 12T > A 15/200 21, 34, 35, Current studya
IVS53 c.8441 − 32G > C 42/200 21, 33–35, Current studya
IVS54 c.8643 − 73C > T 27/200 34, Current studya
IVS54 c.8643 − 24A > G 10/200 21, 34, 35, Current studya
IVS55 c.8798 − 19A > C 9/200 21, 34, 35, Current studya
IVS57 c.8797 + 19A > C 0/200 D: 0.98 D: 0.98 Probably no effect Novel
IVS58 c.9829 + 70T > G 0/200 D: 0.93 D: 0.93 Probably no effect Novel
IVS61 c.11174 + 10A > G 0/200 D: 1.00 D: 1.00 Probably no effect Novel
IVS61 c.11174 + 11A > G 5/200 21, 33, 35, Current studya
IVS61 c.11174 + 26A > G 0/200 D: 1.00 D: 1.00 Probably no effect Novel
IVS62 c.11310 + 19C > T 0/200 D: 0.89 D: 0.89 Probably no effect Novel
21Bergmann et al, 2003.
33Rossetti et al, 2003.
34Furu et al, 2003.
35Bergmann et al, 2004.
aSharp et al, database submission.
GenBank NT 007592.13; NM 138694.2; nucleotide +1 is the A of the ATG-translation initiation codon.
Abbreviations are: SS, splice-site score using the splice-site prediction algorithm at http://www.fruitfly.org/seq tools/splice.html; A; splice acceptor site; D, donor
splice site; WT, wild-type; ND; not detected (in cases where the above mentioned algorithm did not predict an acceptor/donor splice site neither for the WT nor for the
variant sequence, a further splice site prediction algorithm at http://www.cbs.dtu.dk/services/NetGene2/ was used, results are given in parentheses).
in the ARPKD population and segregation with the dis-
ease might finally be the best evidence that a change is
in fact disease associated. Difficulties in evaluating the
pathogenicity of some mutations emphasize the need to
catalogue all PKHD1 changes in a locus specific database
(http://www.humgen.rwth-aachen.de).
The major cause of missing mutations in a consider-
able proportion of alleles may be limited sensitivity of
the screening method even though DHPLC has been
shown to be efficient and effective in analyzing large
genes [45–47]. Further reasons for failure to detect mu-
tations may be changes residing in regulatory elements
or introns distant from the splice donor and acceptor
sites that have not been screened, but which may lead
to aberrant splicing [32, 48, 49]. Moreover, some of the
changes currently categorized as nonpathogenic may ul-
timately turn out to be disease associated. It might be
hypothesized that some silent exonic changes and a sub-
set of adjacent intronic sequence variations do also have
an effect on PKHD1 splicing [e.g., by affecting splice en-
hancer or silencer sites (ESE/ISE or ESS/ISS)]. However,
at present stage of knowledge we categorized them as
nonpathogenic changes. Functional and mRNA studies
are needed to prove any possible pathogenic effect. In
patients without a detectable PKHD1 mutation misdiag-
nosis of ARPKD has to be considered. However, normal
parental ultrasound scans and typical clinical and sono-
graphic features were documented in any of the five cases
of the present study. In one patient, CHF has even been
confirmed histologically. Moreover, although the disease
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Table 6. Categorization of recurrent PKHD1 missense mutations
Pedigrees Peri-/neonatal Gross intrafamilial Moderate
Missense mutation (patients) demise variation phenotype Implication
I473S/I473S 2 (2) 2 (2) Moderate
I1687T/X 2 (3) 2 (3) Moderate
I2957T/X 2 (2) 2 (2) Moderate
I3468V/X 2 (2) 2 (2) Moderate
I222V/X 6 (10) 2 (3/2) 4 (5) Rather moderate
Y1838C/Y1838C 3 (3) 3 (3) Rather moderate
Y1838C/X 1 (1) 1 (1)
I1998T/I1998T 1 (1) 1 (1) Rather moderate
I1998T/X 1 (2) 1 (1/1)
I2331K/X 4 (6) 1 (1/1) 3 (4) Rather moderate
T36M/T36M 2 (3) 1 (1) 1 (1/1) Rather severe
T36M/X 12 (15) 11 (13) 1 (2)
R760H/R760H 2 (4) 1 (1) 1 (2/1) Rather severe
H3124Y/H3124Y 2 (2) 1 (1) 1 (1)
H3124Y/X 1 (1) 1 (1) Rather severe
V3471G/X 5 (5) 3 (3) 2 (2) Rather severe
P805L/X 2 (2) 2 (2) Severe
G1122S/X 2 (2) 2 (2) Severe
I2303F/X 3 (3) 3 (3) Severe
I3177T/X 2 (2) 2 (2) Severe
R3482C/R3482C 2 (5) 2 (5) Severe
Recurrent PKHD1 missense mutations (occurring in at least two unrelated families) have been classified in case of a truncating mutation on the other parental
allele or in case of a homozygous amino acid substitution. The number of patients carrying the respective change is given in parentheses. In case of gross intrafamilial
variability among siblings, the number of severely and moderately affected patients is separated by a slash.
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is linked to PKHD1 in the vast majority of ARPKD fam-
ilies, locus heterogeneity has to be considered in cases
without PKHD1 mutation.
Genotype-phenotype correlations
This study corroborates earlier genotype-phenotype
correlations for the type of PKHD1 mutation [21]. All
patients carrying two truncating mutations displayed a
severe phenotype with peri-/neonatal demise, whereas
patients surviving the neonatal period bear at least one
missense mutation. Although the converse did not apply
and some missense changes are obviously as devastat-
ing as truncating mutations, missense changes are more
frequently observed among patients with a milder clini-
cal course, while chain-terminating mutations are more
commonly associated with a severe phenotype.
Loss of function probably explains the uniformly early
demise of patients carrying two truncating alleles. In con-
trast, missense mutations may have more variable effects
on protein’s function. Some might result in hypomor-
phic alleles with reduced function allowing for a clini-
cally milder course, whereas others may represent loss-
of-function variants. As depicted by discordant siblings,
phenotypes cannot be simply explained on the basis of
the genotype, but likely depend on the background of
other genes [50, 51], epigenetic factors (e.g., alternative
splicing [32, 49, 52, 53]), and environmental influences
as well. Such modifiers will probably have their great-
est impact on the phenotype in the setting of hypomor-
phic missense changes and may explain, at least in part,
the highly variable clinical course resulting from missense
mutations, whereas they are less likely to be relevant in
loss-of-function alleles.
Phenotypes may further be influenced by the location
and character of amino acid substitutions. It might thus
be reasonable to categorize PKHD1 missense mutations
into severe and moderate/mild changes as done for var-
ious other disorders [54, 55]. However, multiple allelism
and the high rate of different compound heterozygotes
hamper genotype-phenotype correlations. In a simplified
approach to classify mutations, termination-type muta-
tions represent loss-of-function alleles with a uniform ef-
fect on phenotype. Thus, one would expect the position
and character of the missense change to determine the
clinical course in compound heterozygotes with one trun-
cating and one missense mutation. As a matter of course,
conclusions should be dealt tentatively given the still lim-
ited dataset, even if PKHD1 missense mutations have
only been classified in case of recurrence in at least two
unrelated families either homozygously or in compound
with a truncating mutation on the other parental allele
(Table 6).
We tested the hypothesis that differences in the clin-
ical course observed among the study cohort resulted
from the type of mutations. We focused on those patients
in whom we had identified two putative mutations and
subdivided this cohort into patients carrying missense al-
terations on both parental alleles and a group charac-
terized by the presence of a truncating change. The lat-
ter cohort was supplemented by patients in whom only
a chain-terminating mutation is known while the sec-
ond pathogenic allele remains to be identified. It is most
likely that the unidentified mutation in these patients is
an amino acid substitution given the strong correlation
that survival past the neonatal period invariably requires
the presence of at least one missense mutation.
We first compared the nature of mutations among pa-
tients who required renal replacement therapy. One may
hypothesize that ESRD occurred earlier in individuals
with a chain-terminating change than in patients with
two amino acid substitution mutations. In fact, the mean
age when renal replacement therapy was required was
considerably lower in the former group (7.2 versus 10.1
years). However, the small number of patients included in
each subgroup does not allow meaningful statistical com-
parisons. The same applies for correlations regarding the
development of renal function depicted in Figure 3. The
mean age at which patients with a truncating mutation
on one parental allele reached a serum creatinine value
of about 200 lmol/L was earlier than in patients carrying
two missense changes (4.1 versus 7.2 years), however, the
clinical events examined were too few in number.
We further compared the mutation spectrum of pa-
tients requiring renal replacement therapy (N = 38) with
those of individuals with a minimum age of 15 years and
a serum creatinine <200 lmol/L (N = 20). There was a
slight overpresentation of missense changes in the mildly
affected cohort (71% versus 80%) (NS). We checked
the sites of missense mutations to look for protein re-
gions associated with a specific phenotype. One muta-
tion, Y1838C (exon 34), was homozygously observed in
three Turkish patients with early ESRD. This suggests this
portion of PKHD1 to be particularly important for renal
integrity. This hypothesis is further corroborated by RTX
patient ID149 who carries the adjacent change W1834C
in compound with a nonsense mutation.
Furthermore, we questioned if the mutational spec-
trum among patients with a predominant liver pheno-
type [early esophageal variceal bleeding or ascites and
(nearly) normal renal function] (N = 15) differed from
that of patients without clinical hepatobiliary manifesta-
tion at age 15 (N = 17). While missense changes were
comparably distributed among the two groups (70% ver-
sus 78%) (NS), mutations of patients with a predominant
liver phenotype clustered around amino acids 2831-2840
(exon 54) and 3051-3209 (exon 58). However, given the
limited number of patients further functional and muta-
tional studies in PKHD1 will have to be awaited before
profound conclusions can be drawn from these data.
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While the majority of sibships display comparable clin-
ical courses, about 20% of ARPKD multiplex pedigrees
exhibit gross intrafamilial phenotypic variability (own un-
published data of more than 100 multiplex pedigrees)
[56]. The even higher proportion of 20 out of 48 sibships
(42%) in the current survey is biased due to the study
design with at least one neonatal survivor per family.
Adjusted for differing family sizes the risk for perinatal
demise of a further affected child was 37% (22 perinatally
deceased children from a total of 59 patients excluding
the moderately affected index cases). For genetic coun-
seling this rate is alarming given that our study cohort is
representative for the spectrum of patients followed by
departments of pediatric nephrology. Of course, pheno-
type categorization into severe and moderate is a sim-
plified view given the considerably better prognosis for
patients surviving the most critical neonatal period [7].
For instance, survival of an individual might depend on
available intensive care facilities or birth order whether
the parents are aware of ARPKD risk. In 14 of the over-
all 20 sibships with gross phenotypic variability included
in the present study the peri-/neonatally deceased sib-
ling was the first born affected child. Nevertheless, some
alertness should be warranted in predicting the clinical
outcome of a further affected child.
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